More on COAG
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $44.53 |
|
|||
| Open | $43.58 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $50.11 | ||||
| Day Low | $43.26 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 320,013 | ||||
- Hemab shares sutacimig Phase 2 data at ISTH 2026 congress
- Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
- Hemab Therapeutics Holdings (COAG) PT Raised to $47 at Jefferies
- Hemab Therapeutics Holdings (COAG) PT Raised to $52 at H.C. Wainwright
- Hemab shares clinical data on HMB-002, unveils HMB-003 program
- Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
- Hemab Therapeutics to present pipeline data at ISTH 2026
- Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
- Form 4 Hemab Therapeutics Holdi For: Jun 15 Filed by: Kolchinsky Peter
- H.C. Wainwright Starts Hemab Therapeutics Holdings (COAG) at Buy
Entities mentioned with COAG
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- IPO | View Related Stories »
- Jefferies & Co | View Related Stories »
- FDA | View Related Stories »
- Goldman Sachs | View Related Stories »
- 13G | View Related Stories »
- Show More...
